In addition, they compared the levels of CSF p-tau 181, p-tau217, t-tau, and tau368 and their correlation with tau burden in cognitively unimpaired, mild cognitive impairment, non-AD cognitive disorder, and AD dementia patients. This evidence concerns the gene MAPT and Cognitive impairment.